Sartorius Aktiengesellschaft SRT3.DE
Composite 41/100; the shares have moved about 43% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Valuation ranks 24/100 — a strong mark against it.
Growth ranks 58/100 — a slight point in its favour. Momentum ranks 54/100 — a slight point in its favour.
Valuation ranks 24/100 — a strong mark against it. Balance-sheet strength ranks 29/100 — a moderate mark against it. Income ranks 35/100 — a moderate mark against it.
What the company does Sartorius Aktiengesellschaft (SRT3.DE) supplies bioprocess, lab filtration/purification, and analytical solutions to pharma, cell & gene therapy, and life-science research. Its portfolio spans bioreactors, chromatography systems, lab consumables, and data-analytics tools used across drug development and manufacturing workflows.
Key financials Revenue grew 3% YoY while EPS surged 239%, reflecting margin recovery and operational leverage. Gross margin sits at 46%, operating margin 18%, and net margin 6%. ROE is 7%, ROA 4%, and ROCE 8%, with a Piotroski F-Score of 7/9 and Altman Z of 2.63 indicating moderate financial health.
Stock health Momentum is mixed: +18% over 12m but -6% over 6m and -15% below the 52-week high; RSI(14) at 47.5 signals neutral momentum. The current ratio is 1.14 and debt/EBITDA is 4.01, with interest coverage at 2.7x, suggesting manageable liquidity and leverage.
Price vs fair value The stock trades at a PREMIUM of 61.80% versus our fair-value estimate of 86.29 and at a discount of 17.88% to the 12-month target of 265.95. - Forward P/E of 39x and P/E of 79x are rich versus peers (Valuation 27.1/100). - PEG of 0.39 reflects high growth expectations (Growth 56.2). - Net margin of 6% lags Quality peers (Quality 47.5). - 12-month price return of +18% contrasts with 6-month decline of -6% (Momentum 47.9).
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-04, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.